Clinical Trial Update: Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the activity of combining nivolumab and ipilimumab in patients with recurrent or persistent clear cell ovarian cancer, and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-12-23